Compare LGL & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | DARE |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 27.6M |
| IPO Year | N/A | N/A |
| Metric | LGL | DARE |
|---|---|---|
| Price | $5.70 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 8.8K | ★ 315.0K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 149.85 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $4,107,000.00 | N/A |
| Revenue This Year | N/A | $3,838.11 |
| Revenue Next Year | N/A | $8,711.98 |
| P/E Ratio | $33.84 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.45 | $1.61 |
| 52 Week High | $9.74 | $9.19 |
| Indicator | LGL | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 46.57 |
| Support Level | $5.57 | $2.05 |
| Resistance Level | $5.90 | $2.24 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 47.98 | 10.16 |
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.